A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)

  • Better, Nathan (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date22/01/25 → 21/01/27

Keywords

  • Clinical Trials
  • TX000045-003

Clinical Trial Phase

  • Phase II